Yalonda Howze - 19 Jan 2022 Form 4 Insider Report for Codiak BioSciences, Inc. (CDAKQ)

Role
Officer title: Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary
Signature
/s/ Yalonda Howze
Issuer symbol
CDAKQ
Transactions as of
19 Jan 2022
Net transactions value
$0
Form type
4
Filing time
21 Jan 2022, 15:05:38 UTC
Next filing
18 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CDAKQ Stock Option (Right to Buy) Award $0 +52,000 $0.000000 52,000 19 Jan 2022 Common Stock 52,000 $7.21 Direct F1
transaction CDAKQ Restricted Stock Units Award $0 +12,000 $0.000000 12,000 19 Jan 2022 Common Stock 12,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest and become exercisable on January 19, 2023, with the remainder vesting in 12 equal quarterly installments thereafter.
F2 Each restricted stock unit represents a contingent right to receive one share of common stock.
F3 On January 19, 2022, the reporting person was granted 12,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.

Remarks:

Officer title: Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary